| 溶解性 | DMSO 111 mg/mL Water <1 mg/mL Ethanol 16 mg/mL |
| 存贮条件 | 储存温度-20°C |
| 备注 | DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2. |
| 生化机理 | The lead "switch-control" inhibitor, DCC-2036, potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conformation, and retains efficacy against the majority of clinically relevant CML-resistance mutants, including T315I. DCC-2036 inhibits autophosphorylation of ABL and ABLT315I enzymes, and this activity was consistent with selective efficacy against Ba/F3 cells expressing BCR-ABL (IC50: 19 nmol/L), BCR-ABLT315I (IC50: 63 nmol/L), and most kinase domain mutants. These findings support continued evaluation of DCC-2036 as an important new agent for treatment-refractory CML. |
| 别名 | 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea;1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea |
DCC-2036 (Rebastinib),抑制剂
DCC-2036 (Rebastinib) （订货以英文为准）
编号：D126373
CAS号：1020172-07-9
分子式：C30H28FN7O3
分子量：553.59
| 产品名称 | DCC-2036 (Rebastinib) |
| 中文名称 | DCC-2036 (Rebastinib),抑制剂 |
| CAS号 | 1020172-07-9 |
| 分子式（M.F.） | C30H28FN7O3 |
| 分子量（M.W.） | 553.59 |
| 储存条件 | -20°C储存 |
| 标识符号 | https://www.aladdin-e.com/images/ghs/ghs07.jpg |
| 信号词 | Warning |
| 危害声明 | H315-H319-H335 |
| 警示性声明 | P261-P305 + P351 + P338 |
| 个人防护设备 | dust mask type N95 (US), Eyeshields, Gloves |
| WGK德国 | 3 |
搜索质检报告(COA)
搜索MSDS
相关产品
党沛 
